Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity
View Patent ↗Compounds that modulate the action of ACK1 and LCK, and related compositions methods for treating ACK1- and LCK-mediated diseases are described. In one aspect, the compounds have the general structure: where the values of the substituents are provided herein.
1. A compound having the structure:
including stereoisomers thereof, tautomers thereof, and pharmaceutically acceptable salts thereof, wherein:
R 1 is —OR 5 , —SR 5 , or —NHR 5 ;
R 2 and R 3 independently are aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, arylalkyl, substituted arylalkyl, (heteroaryl)alkyl, substituted (heteroaryl)alkyl, (cycloalkyl)alkyl, substituted (cycloalkyl)alkyl, (cycloheteroalkyl)alkyl, or substituted (cycloheteroalkyl)alkyl;
R 4 is hydrogen, alkyl, substituted alkyl, alkylcarbonyl, substituted alkylcarbonyl, arylcarbonyl, substituted arylcarbonyl, arylalkylcarbonyl, substituted arylalkylcarbonyl, alkylsulfonyl, substituted alkylsulfonyl, arylsulfonyl, substituted arylsulfonyl, arylalkylsulfonyl, substituted arylalkylsulfonyl, trialkylsilyl, substituted trialkylsilyl, triarylalkylsilyl, substituted triarylalkylsilyl, formyl, diarylthiophosphinyl, or substituted diarylthiophosphinyl; and
R 5 is a (cycloheteroalkyl)alkyl or substituted (cycloheteroalkyl)alkyl moiety, wherein the cycloheteroalkyl portion of said moiety is a saturated ring.
2. The compound of claim 1 , wherein R 1 is —NHR 5 .
3. The compound of claim 2 , wherein R 2 and R 3 independently are aryl, substituted aryl, heteroaryl, or substituted heteroaryl.
4. The compound of claim 3 , wherein R 2 and R 3 independently are aryl or substituted aryl.
5. The compound of claim 4 , wherein R 2 and R 3 independently are phenyl or substituted phenyl.
6. The compound of claim 5 , wherein R 2 and R 3 are phenyl.
7. The compound of claim 5 , wherein R 2 is phenyl.
8. The compound of claim 7 , wherein R 3 is phenyl substituted with a moiety selected from the group consisting of: alkylaminosulfonyl, dialkylaminosulfonyl, (heterocycloalkyl)alkylaminosulfonyl, di(alkyloxyalkyl)aminosulfonyl, alkyloxyalkylaminosulfonyl, N-morpholinosulfonyl, N-morpholinoalkylaminosulfonyl, carboxylakylaminosulfonyl, alkyloxycarbonylalkylaminosulfonyl, alkylaminocarbonyl, dialkylaminocarbonyl, (heterocycloalkyl)alkylaminocarbonyl, di(alkyloxyalkyl)aminocarbonyl, alkyloxyalkylaminocarbonyl, N-morpholinocarbonyl, N-morpholinoalkylaminocarbonyl, carboxylakylaminocarbonyl, alkyloxycarbonylalkylaminocarbonyl, cycloalkylamioncarbonyl, alkyloxy, alkylaminoalkyloxy, (dialkylamino)alkyloxy, N-morpholinoalkyloxy, or N-azacycloalkylalkyloxy, wherein each of the foregoing substituents is itself optionally substituted.
9. The compound of claim 8 , wherein R 5 is tetrahydrofuranylalkyl.
10. The compound of claim 9 , wherein R 5 is (tetrahydrofuran-2-yl)methyl.
11. A compound having the structure:
including stereoisomers thereof, tautomers thereof, and pharmaceutically acceptable salts thereof, wherein:
R 6 is a (cycloheteroalkyl)methyl moiety, wherein the cycloheteroalkyl portion of said moiety is a saturated 5- or 6-membered heteroalkyl ring containing at least one oxygen or sulfur heteroatom;
R 7 is aryl or heteroaryl, each optionally substituted with alkylaminosulfonyl, dialkylaminosulfonyl, (heterocycloalkyl)alkylaminosulfonyl, di(alkyloxyalkyl)aminosulfonyl, alkyloxyalkylaminosulfonyl, N-morpholinosulfonyl, N-morpholinoalkylaminosulfonyl, carboxylakylaminosulfonyl, alkyloxycarbonylalkylaminosulfonyl, alkylaminocarbonyl, dialkylaminocarbonyl, (heterocycloalkyl)alkylaminocarbonyl, di(alkyloxyalkyl)aminocarbonyl, alkyloxyalkylaminocarbonyl, N-morpholinocarbonyl, N-morpholinoalkylaminocarbonyl, carboxylakylaminocarbonyl, alkyloxycarbonylalkylaminocarbonyl, cycloalkylamioncarbonyl, alkyloxy, alkylaminoalkyloxy, (dialkylamino)alkyloxy, N-morpholinoalkyloxy, or N-azacycloalkylalkyloxy, wherein each of the foregoing optional substituents is itself optionally substituted; and
R 8 is hydrogen, alkyl, substituted alkyl, alkylcarbonyl, substituted alkylcarbonyl, arylcarbonyl, substituted arylcarbonyl, arylalkylcarbonyl, substituted arylalkylcarbonyl, alkylsulfonyl, substituted alkylsulfonyl, arylsulfonyl, substituted arylsulfonyl, arylalkylsulfonyl, substituted arylalkylsulfonyl, trialkylsilyl, substituted trialkylsilyl, triarylalkylsilyl, substituted triarylalkylsilyl, formyl, diarylthiophosphinyl, or substituted diarylthiophosphinyl.
12. The compound of claim 11 , wherein R 7 is aryl.
13. The compound of claim 12 , wherein R 7 is phenyl.
14. The compound of claim 12 , wherein R 6 is tetrahydrofuranylmethyl.
15. The compound of claim 13 , wherein R 6 is (tetrahydrofuran-2-yl)methyl.
16. The compound of claim 14 , wherein R 6 is ((S)-tetrahydrofuran-2-yl)methyl.
17. The compound of claim 11 , wherein R 6 is tetrahydrofuranylmethyl.
18. The compound of claim 17 , wherein R 6 is (tetrahydrofuran-2-yl)methyl.
19. The compound of claim 18 , wherein R 6 is ((S)-tetrahydrofuran-2-yl)methyl.
20. The compound of claim 1 , wherein said compound is selected from the group consisting of:
(5,6-Diphenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-(2-morpholin-4-ylethyl)-amine,
(5,6-Diphenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-(tetrahydrofuran-2-ylmethyl)-amine,
(5,6-Diphenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-(tetrahydrothiophen-2-ylmethyl)-amine,
(5,6-Diphenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-(tetrahydropyran-2-ylmethyl) amine,
N,N-Dimethyl-4-{5-phenyl-4-[(tetrahydro-furan-2-ylmethyl)-amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl}-benzenesulfonamide,
N-Methyl-4-{5-phenyl-4-[(tetrahydrofuran-2-ylmethyl)-amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl}-benzenesulfonamide,
N,N-Diethyl-4-{5-phenyl-4-[(tetrahydrofuran-2-ylmethyl)-amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl}-benzenesulfonamide,
N,N-Bis-(2-methoxyethyl)-4-{5-phenyl-4-[(tetrahydrofuran-2-ylmethyl)-amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl}-benzenesulfonamide,
N-(2-Methoxyethyl)-4-{5-phenyl-4-[(tetrahydrofuran-2-ylmethyl)-amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl}-benzenesulfonamide,
{6-[4-(Morpholin-4-sulfonyl)-phenyl]-5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-(tetrahydrofuran-2-ylmethyl)-amine,
N-(2-Morpholin-4-yl-ethyl)-4-{5-phenyl-4-[(tetrahydrofuran-2-ylmethyl)-amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl}-benzenesulfonamide,
N-Allyl-4-{5-phenyl-4-[(tetrahydro-furan-2-ylmethyl)-amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl}-benzenesulfonamide,
(4-{5-Phenyl-4-[(tetrahydrofuran-2-ylmethyl)-amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl}-benzenesulfonylamino)-acetic acid tert-butyl ester,
[Ethoxycarbonylmethyl-(4-{5-phenyl-4-[(tetrahydrofuran-2-ylmethyl)-amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl}-benzenesulfonyl)-amino]-acetic acid ethyl ester,
4-{5-Phenyl-4-[(tetrahydrofuran-2-ylmethyl)-amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl}.
21. A method for treating prostate cancer, lung cancer, or ovarian cancer in an animal, comprising administering to such animal a therapeutically effective amount of a compound of claim 1 .
22. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 in a pharmaceutically effective carrier.